title: [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
abstract: The study was made of dalphas-retard safety and effectiveness in 940 patients with benign prostatic hyperplasia and relevant urination problems. The drug was given in a dose 5-10 mg/day for 12 weeks. The results were assessed in 881 patients who had completed the treatment course. 18 patients (1.9%) discontinued the treatment because of side effects. 38 patients (4%) had side effects once or more times.
authors.forename: O B
authors.initials: OB
authors.lastname: Loran
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Pushkar'
authors.forename: P I
authors.initials: PI
authors.lastname: Rasner
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D012449:Safety; D014554:Urination / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy / Q000209:etiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin